Rare Diseases Clinical Trials Update: Week 44, 2026

Published October 30, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency

This Phase 3 trial is testing an oral medication called pyridoxal 5'-phosphate for people with PNPO deficiency, a rare genetic disorder that affects how the body processes certain vitamins important for brain function. Currently, there is no approved pharmaceutical treatment, so this study could provide a new option to help manage symptoms and improve quality of life. The trial is active but not recruiting, involving 15 patients across the United States and Australia.

Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children

This Phase 3 trial is evaluating an investigational gene therapy for children with recurrent respiratory papillomatosis, a rare condition where noncancerous growths caused by HPV block the airways. The treatment aims to reduce the number of surgeries these children need by helping their immune system control the growths. The study is currently recruiting in the United States and will follow participants for up to five years after receiving treatment.

Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH

This trial is assessing the safety of a preservative-free form of treprostinil for children with pulmonary arterial hypertension, a serious condition that affects blood flow in the lungs. If shown to be safe and better tolerated, this medication could offer a new treatment option for young patients. The study is recruiting across five European countries and will monitor children for about five months.

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

This Phase 2 trial is testing a drug called SRX246 to reduce irritability and aggression in adult males with Fragile X Syndrome, a genetic condition that can cause intellectual disability and behavioral challenges. A successful treatment could help improve daily life for patients and their families. The study is recruiting in the United States, with participants taking medication daily and attending regular check-ins over eight months.

Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy

This study is exploring a new way to monitor Duchenne Muscular Dystrophy using non-invasive urine and blood tests instead of muscle biopsies. This approach could make it easier and less painful for patients to track how the disease is progressing. The trial is recruiting in the United States and plans to enroll about 100 participants.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.